GenSight Biologics has announced the publication of five-year outcomes data for LUMEVOQ®, their investigational gene therapy for Leber Hereditary Optic Neuropathy, highlighting sustained improvements in patients' visual acuity and safety.
Company Information
Company
GenSight Biologics
Location
Paris, Ile-de-France, France
About
GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GenSight Biologics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ParisBiotechnologyHealth CareTherapeuticsBiopharma